Stay updated on Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-30T04:37:08.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.0, replacing the previous version 2.15.2.
    Difference
    0.3%
    Check dated 2025-05-23T01:59:28.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T06:09:10.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The page has undergone significant content changes, including the removal of detailed study information regarding pembrolizumab for squamous cell carcinoma of the head and neck, while adding a new version revision and collaborators.
    Difference
    43%
    Check dated 2025-04-16T17:01:10.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T12:51:32.000Z thumbnail image
  7. Check
    97 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-02-24T22:38:09.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.